This preclinical study evaluated a nanoparticle delivery platform designed to promote mucosal healing and modulate immune responses in inflammatory bowel disease models. The research demonstrated that the nanoparticle formulation containing KPV (a tripeptide) enhanced intestinal barrier function and reduced inflammatory markers in laboratory and animal model systems. This represents early-stage evidence (animal model/in vitro) requiring further human clinical testing before any therapeutic application can be established.